{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:40:44Z","timestamp":1791348044566,"version":"4.3.1"},"reference-count":36,"publisher":"Aboutscience Srl","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Circ Biomark"],"abstract":"<jats:p>Background: Systemic inflammation is crucial in cancer cachexia, but the optimal measurement method remainsunclear. This study compares markers of systemic inflammation (MoSI) in predicting weight loss in patients withmetastatic cancer.Methods: This prospective, observational multi-center study involved patients undergoing radiotherapy forbone metastases. Baseline assessments included demographics, clinical characteristics, previous weight loss,and appetite loss. MoSI included: C-reactive protein (CRP), albumin, white blood cells, neutrophil-to-lymphocyteratio, monocyte-to-lymphocyte ratio, interleukin-6 (IL-6), modified Glasgow Prognostic Score (mGPS), andPrognostic Nutritional Index. Body weight was recorded at baseline, 3, and 8 weeks post-radiotherapy. Multiplelinear regression assessed MoSI\u2019s predictive ability for weight loss, adjusting for previous weight loss, appetiteloss, and primary tumour type. Goodness-of-fit was assessed using adjusted R2.Results: Out of 574 recruited patients, 540 and 470 were analyzed at 3 and 8 weeks, respectively. The median age(IQR) was 67 (15), 330 (61%) were male, and 397 (74%) had a Karnofsky performance status \u226570. In a base modelwithout MoSI, significant predictors of weight loss at 3 weeks were appetite loss and urological, lung, and gastrointestinalcancer (adjusted R2 of 0.064), while at 8 weeks, urological and lung cancer were significant (adjusted R2of 0.035). At 3 weeks, all MoSI significantly improved the base model, with adjusted R2 between 0.078 and 0.091.At 8 weeks: CRP, mGPS, albumin and IL-6 improved the model; however only CRP and mGPS retained an adjustedR2 of ~0.09.Conclusions: All MoSI predicted weight loss, but CRP and mGPS were the most optimal.<\/jats:p>","DOI":"10.33393\/jcb.2025.3510","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:15:48Z","timestamp":1753708548000},"page":"12-20","source":"Crossref","is-referenced-by-count":5,"title":["A comparison of inflammatory markers\u2019 potential to predict weight loss in advanced cancer: a prospective observational study"],"prefix":"10.33393","volume":"14","author":[{"given":"Ola Magne","family":"Vagnildhaug","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild H.","family":"Habberstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8yvind","family":"Salvesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trude R.","family":"Balstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asta","family":"Bye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olav","family":"Dajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e5l","family":"Klepstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tora S.","family":"Solheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18642","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"17100","doi-asserted-by":"crossref","unstructured":"Vagnildhaug OM, Balstad TR, Almberg SS, et al. A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer. Support Care Cancer. 2018;26(6):1871-1880. https:\/\/doi.org\/10.1007\/s00520-017-4022-z PMID:29274028","DOI":"10.1007\/s00520-017-4022-z"},{"key":"17101","doi-asserted-by":"crossref","unstructured":"Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489-495. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7 PMID:21296615","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"17102","doi-asserted-by":"crossref","unstructured":"Solheim TS, Laird BJA, Balstad TR, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(5):778-788. https:\/\/doi.org\/10.1002\/jcsm.12201 PMID:28614627","DOI":"10.1002\/jcsm.12201"},{"key":"17103","doi-asserted-by":"crossref","unstructured":"Takayama K, Katakami N, Yokoyama T, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016;24(8):3495-3505. https:\/\/doi.org\/10.1007\/s00520-016-3144-z PMID:27005463","DOI":"10.1007\/s00520-016-3144-z"},{"key":"17104","doi-asserted-by":"crossref","unstructured":"Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17(4):519-531. https:\/\/doi.org\/10.1016\/S1470-2045(15)00558-6 PMID:26906526","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"17105","doi-asserted-by":"crossref","unstructured":"Fearon KC, Glass DJ, Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012;16(2):153-166. https:\/\/doi.org\/10.1016\/j.cmet.2012.06.011 PMID:22795476","DOI":"10.1016\/j.cmet.2012.06.011"},{"key":"17106","doi-asserted-by":"crossref","unstructured":"Rohm M, Zeigerer A, Machado J, et al. Energy metabolism in cachexia. EMBO Rep. 2019;20(4):e47258. https:\/\/doi.org\/10.15252\/embr.201847258 PMID:30890538","DOI":"10.15252\/embr.201847258"},{"key":"17107","doi-asserted-by":"crossref","unstructured":"Cederholm T, Jensen GL, Correia M, et al. GLIM criteria for the diagnosis of malnutrition - a consensus report from the global clinical nutrition community. Clinical nutrition (Edinburgh, Scotland). 2018. DOI: 10.1016\/j.clnu.2018.08.002","DOI":"10.1016\/j.clnu.2019.02.033"},{"key":"17108","doi-asserted-by":"crossref","unstructured":"Yule MS, Thompson J, Leesahatsawat K, et al. Cancer Cachexia Endpoints Working Group. Biomarker endpoints in cancer cachexia clinical trials: systematic Review 5 of the cachexia endpoint series. J Cachexia Sarcopenia Muscle. 2024;15(3):853-867. https:\/\/doi.org\/10.1002\/jcsm.13491 PMID:38783477","DOI":"10.1002\/jcsm.13491"},{"key":"17109","doi-asserted-by":"crossref","unstructured":"Dewys WD, Begg C, Lavin PT, et al. Eastern Cooperative Oncology Group. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med. 1980;69(4):491-497. https:\/\/doi.org\/10.1016\/S0149-2918(05)80001-3 PMID:7424938","DOI":"10.1016\/S0149-2918(05)80001-3"},{"key":"17110","doi-asserted-by":"crossref","unstructured":"Ross PJ, Ashley S, Norton A, et al. Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 2004;90(10):1905-1911. https:\/\/doi.org\/10.1038\/sj.bjc.6601781 PMID:15138470","DOI":"10.1038\/sj.bjc.6601781"},{"key":"17111","doi-asserted-by":"crossref","unstructured":"Chen IM, Johansen JS, Theile S, et al. Randomized phase II study of Nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in advanced pancreatic cancer: survival and cachexia. Journal of Clinical Oncology. 2025;0(0):JCO.23.01965. DOI: 10.1200\/JCO.23.01965","DOI":"10.1200\/JCO.23.01965"},{"key":"17112","doi-asserted-by":"crossref","unstructured":"Groarke JD, Crawford J, Collins SM, et al. Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design. J Cachexia Sarcopenia Muscle. 2024;15(3):1054-1061. https:\/\/doi.org\/10.1002\/jcsm.13435 PMID:38500292","DOI":"10.1002\/jcsm.13435"},{"key":"17113","doi-asserted-by":"crossref","unstructured":"Vagnildhaug OM, Brunelli C, Hjermstad MJ, et al. A prospective study examining cachexia predictors in patients with incurable cancer. BMC Palliat Care. 2019;18(1):46. https:\/\/doi.org\/10.1186\/s12904-019-0429-2 PMID:31164115","DOI":"10.1186\/s12904-019-0429-2"},{"key":"17114","doi-asserted-by":"crossref","unstructured":"Habberstad R, Aass N, Mollnes TE, et al. Inflammatory markers and radiotherapy response in patients with painful bone metastases. J Pain Symptom Manage. 2022;64(4):330-339. https:\/\/doi.org\/10.1016\/j.jpainsymman.2022.06.018 PMID:35803553","DOI":"10.1016\/j.jpainsymman.2022.06.018"},{"key":"17115","doi-asserted-by":"crossref","unstructured":"von Elm E, Altman DG, Egger M, et al. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X PMID:18064739","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"17116","doi-asserted-by":"crossref","unstructured":"Vigano AL, di Tomasso J, Kilgour RD, et al. The abridged patient-generated subjective global assessment is a useful tool for early detection and characterization of cancer cachexia. J Acad Nutr Diet. 2014;114(7):1088-1098. https:\/\/doi.org\/10.1016\/j.jand.2013.09.027 PMID:24462323","DOI":"10.1016\/j.jand.2013.09.027"},{"key":"17117","doi-asserted-by":"crossref","unstructured":"Groenvold M, Petersen MA, Aaronson NK, et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. European journal of cancer (Oxford, England : 1990). 2006;42(1):55\u201364. DOI: 10.1016\/j.ejca.2005.06.022","DOI":"10.1016\/j.ejca.2005.06.022"},{"key":"17118","doi-asserted-by":"crossref","unstructured":"Dolan RD, Daly L, Sim WMJ, et al. Comparison of the prognostic value of ECOG-PS, mGPS and BMI\/WL: Implications for a clinically important framework in the assessment and treatment of advanced cancer. Clinical nutrition (Edinburgh, Scotland). 2019. DOI: 10.1016\/j.clnu.2019.12.024","DOI":"10.1016\/j.clnu.2019.12.024"},{"key":"17119","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Kawada K, Obama K. Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients. Int J Mol Sci. 2021;22(15):8002. https:\/\/doi.org\/10.3390\/ijms22158002 PMID:34360768","DOI":"10.3390\/ijms22158002"},{"key":"17120","doi-asserted-by":"crossref","unstructured":"Habberstad R, Fr\u00f8seth TCS, Aass N, et al. The Palliative Radiotherapy and Inflammation Study (PRAIS) - protocol for a longitudinal observational multicenter study on patients with cancer induced bone pain. BMC Palliat Care. 2018;17(1):110. https:\/\/doi.org\/10.1186\/s12904-018-0362-9 PMID:30266081","DOI":"10.1186\/s12904-018-0362-9"},{"key":"17121","doi-asserted-by":"crossref","unstructured":"White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377-399. https:\/\/doi.org\/10.1002\/sim.4067 PMID:21225900","DOI":"10.1002\/sim.4067"},{"key":"17122","doi-asserted-by":"crossref","unstructured":"Sun L, Quan XQ, Yu S. An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr Cancer. 2015;67(7):1056-1062. https:\/\/doi.org\/10.1080\/01635581.2015.1073753 PMID:26317149","DOI":"10.1080\/01635581.2015.1073753"},{"key":"17123","doi-asserted-by":"crossref","unstructured":"Iwai N, Sakai H, Oka K, et al. Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support Care Cancer. 2023;31(2):115. https:\/\/doi.org\/10.1007\/s00520-023-07576-y PMID:36640181","DOI":"10.1007\/s00520-023-07576-y"},{"key":"17124","doi-asserted-by":"crossref","unstructured":"Furman D, Campisi J, Verdin E, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832. https:\/\/doi.org\/10.1038\/s41591-019-0675-0 PMID:31806905","DOI":"10.1038\/s41591-019-0675-0"},{"key":"17125","doi-asserted-by":"crossref","unstructured":"Ruan GT, Xie HL, Yuan KT, et al. Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia. J Cachexia Sarcopenia Muscle. 2023;14(6):2813-2823. https:\/\/doi.org\/10.1002\/jcsm.13358 PMID:37902006","DOI":"10.1002\/jcsm.13358"},{"key":"17126","doi-asserted-by":"crossref","unstructured":"Shibutani M, Maeda K, Nagahara H, et al. The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer. Oncol Lett. 2018;16(1):666-672. https:\/\/doi.org\/10.3892\/ol.2018.8628 PMID:29928454","DOI":"10.3892\/ol.2018.8628"},{"key":"17127","doi-asserted-by":"crossref","unstructured":"Blum D, Stene GB, Solheim TS, et al. Validation of the consensus-definition for cancer cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA). Annals of Oncology : Official Journal of the European Society for Medical Oncology\/ESMO. 2014;25(8):1635\u201342. DOI: 10.1093\/annonc\/mdu086","DOI":"10.1093\/annonc\/mdu086"},{"key":"17128","doi-asserted-by":"crossref","unstructured":"Richards CH, Roxburgh CS, MacMillan MT, et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS One. 2012;7(8):e41883. https:\/\/doi.org\/10.1371\/journal.pone.0041883 PMID:22870258","DOI":"10.1371\/journal.pone.0041883"},{"key":"17129","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O, Weiss J, Skrzypski M, et al. TRACERx Consortium. Body composition and lung cancer-associated cachexia in TRACERx. Nat Med. 2023;29(4):846-858. https:\/\/doi.org\/10.1038\/s41591-023-02232-8 PMID:37045997","DOI":"10.1038\/s41591-023-02232-8"},{"key":"17130","doi-asserted-by":"crossref","unstructured":"Robinson TP, Hamidi T, Counts B, et al. The impact of inflammation and acute phase activation in cancer cachexia. Front Immunol. 2023;14:1207746. https:\/\/doi.org\/10.3389\/fimmu.2023.1207746 PMID:38022578","DOI":"10.3389\/fimmu.2023.1207746"},{"key":"17131","doi-asserted-by":"crossref","unstructured":"Aguilar-Cazares D, Chavez-Dominguez R, Marroquin-Muci\u00f1o M, et al. The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. Front Endocrinol (Lausanne). 2022;13:929572. https:\/\/doi.org\/10.3389\/fendo.2022.929572 PMID:36072935","DOI":"10.3389\/fendo.2022.929572"},{"key":"17132","doi-asserted-by":"crossref","unstructured":"Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 2018;124(3):606-616. https:\/\/doi.org\/10.1002\/cncr.31128 PMID:29205286","DOI":"10.1002\/cncr.31128"},{"key":"17133","doi-asserted-by":"crossref","unstructured":"Stewart Coats AJ, Ho GF, Prabhash K, et al. ACT\u2010ONE study group. Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial). J Cachexia Sarcopenia Muscle. 2016;7(3):355-365. https:\/\/doi.org\/10.1002\/jcsm.12126 PMID:27386169","DOI":"10.1002\/jcsm.12126"},{"key":"17134","doi-asserted-by":"crossref","unstructured":"Hasegawa T, Kawahara K, Sato K, et al. Characterization of a cancer-induced bone pain model for use as a model of cancer cachexia. Curr Issues Mol Biol. 2024;46(12):13364-82 DOI: 10.3390\/cimb46120797","DOI":"10.3390\/cimb46120797"},{"key":"17135","doi-asserted-by":"crossref","unstructured":"Nilsonne G, Lekander M, \u00c5kerstedt T, et al. Diurnal variation of circulating interleukin-6 in humans: a meta-analysis. PLoS One. 2016;11(11):e0165799. https:\/\/doi.org\/10.1371\/journal.pone.0165799 PMID:27832117","DOI":"10.1371\/journal.pone.0165799"}],"container-title":["Journal of Circulating Biomarkers"],"original-title":[],"link":[{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3510\/4062","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3510\/4063","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/download\/3510\/4062","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:15:54Z","timestamp":1753708554000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.aboutscience.eu\/index.php\/jcb\/article\/view\/3510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,9]]}},"URL":"https:\/\/doi.org\/10.33393\/jcb.2025.3510","relation":{},"ISSN":["1849-4544","1849-4544"],"issn-type":[{"value":"1849-4544","type":"electronic"},{"value":"1849-4544","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,28]]}}}